Pure Global AI
NCT06371053Not yet recruiting

The Effect of Community Intervention on Different Degrees of Dementia

The Effect of Community Intervention on Different Degrees of Dementia: A Randomized Controlled Study
Babujinaya CelaClinicalTrials.govbehavioral
Study focus
Disease/Condition
Alzheimer Disease
Drug/Device/Intervention
Community Intervention
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Babujinaya Cela
Funder
Buraidah Central Hospital
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
May 01, 2024
Enrollment
200 participants
Primary outcome

Mini-Mental State Examination

Summary

The goal of this clinical trial is to explore the impact of Community Intervention on
 Dementia and Activities of Daily Living in community-dwelling elderly individuals (≥60 year
 old) with Alzheimer's disease. It primarily aims to address: the effects of Community
 Intervention on Dementia and Activities of Daily Living in community-dwelling elderly
 individuals with Alzheimer's disease in different degrees. All participants are required to
 undergo a continuous 2-week (14 days) Community Intervention, with weekends off and training
 conducted only on weekdays. The training will be conducted two sessions per day, lasting 30
 minutes each.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06371053
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06371053 through Pure Global AI's free database. This phase not specified trial is sponsored by Babujinaya Cela and is currently Not yet recruiting. The study focuses on Alzheimer Disease. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.